RECRUITING

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

Talk to us

Conditions

Benign Kidney NeoplasmKidney NeoplasmRenal Cell Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagnostic imaging of tumors. Hyperpolarized 13C pyruvate MRI may help doctors determine non-invasively whether a kidney tumor is a benign tumor or cancer, and if cancer, how aggressive it is. This may help doctors and participants with renal tumors in the future to make better treatment decisions.

Official Title

Hyperpolarized 13C Pyruvate Metabolic MRI to Predict Renal Tumor Aggressiveness

Quick Facts

Study Start:2019-01-15
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04258462

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Renal tumor measuring 1 cm and greater in diameter. To minimize any potential partial volume effects in this pilot study, the investigators have limited the lower size range of the tumor to 1 cm. The investigators will include all renal tumor measuring 1 cm and greater in diameter in this first study to facilitate obtaining tumors of a range of histology and grade.
  2. 2. The participant is being considered by the treating physician to have any of the following management options: partial or radical nephrectomy, ablation, or active surveillance for his/her renal tumor.
  3. 3. The participant is able and willing to comply with study procedures and provide signed and dated informed consent.
  4. 4. The participant is willing to undergo standard of care abdominal MRI in connection with the study exam.
  5. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  1. 1. Participants who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
  2. 2. Participants unwilling or unable to undergo magnetic resonance (MR) imaging, including patients with contra-indications to MR imaging, such as cardiac pacemakers or non-compatible intracranial vascular clips.
  3. 3. Any metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging of the abdomen.
  4. 4. Prior focal therapy (i.e. ablation) for the renal tumor.
  5. 5. Poorly controlled hypertension, with blood pressure at study entry \>160/100. The addition of anti-hypertensives to control blood pressure is allowed for eligibility determination.
  6. 6. Congestive heart failure or New York Heart Association (NYHA) status \>= 2.

Contacts and Locations

Study Contact

Zhen Jane Wang, MD
CONTACT
415-476-3767
Zhen.Wang@ucsf.edu
Maya Aslam
CONTACT
Maya.Aslam@ucsf.edu

Principal Investigator

Zhen Jane Wang, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: Zhen Wang, MD

  • Zhen Jane Wang, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-01-15
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2019-01-15
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Benign Kidney Neoplasm
  • Kidney Neoplasm
  • Renal Cell Cancer